Newsroom | 14329 results

Sorted by: Latest
FDA
-

Bruno Vision Care vince il premio 2026 MedTech Breakthrough

BOCA RATON, Fla.--(BUSINESS WIRE)--Cataltheia Group e la sua controllata statunitense, Bruno Vision Care LLC, azienda leader nell'innovazione della salute degli occhi, oggi hanno annunciato che la loro tecnologia di lente a contatto monouso giornaliera ad aumentata profondità di fuoco (EDOF) per la presbiopia Deseyne® è stata premiata quest'anno con il premio “Best New Technology Solution - Ophthalmology” ai 2026 MedTech Breakthrough Awards. Il programma MedTech Breakthrough Awards riconosce le...
-

Bruno Vision Care Wins 2026 MedTech Breakthrough Award

BOCA RATON, Fla.--(BUSINESS WIRE)--Bruno Vision Care's FDA-cleared Deseyne® Extended Depth of Focus daily disposable contact lens for presbyopia wins 2026 MedTech Breakthrough Award....
-

Actio Biosciences Announces Initiation of KYRON Phase 1b/2 Trial of ABS-1230 for the Treatment of KCNT1-Related Epilepsy and Acceptance into FDA’s Rare Disease Evidence Principles Process

SAN DIEGO--(BUSINESS WIRE)--Actio Biosciences, a clinical-stage biotechnology company advancing the translation of genetic insights into novel precision medicines, today announced the initiation of the KYRON Phase 1b/2 clinical trial of ABS-1230 for the treatment of KCNT1-related epilepsy, a rare, severe and often fatal pediatric developmental epileptic encephalopathy. ABS-1230 is designed to be a potent and selective orally available small molecule KCNT1 inhibitor that addresses the underlying...
-

On World Ovarian Cancer Day, LGSOC Resource Guide Launches to Support People Living with Low-Grade Serous Ovarian Cancer

BOSTON--(BUSINESS WIRE)--Today, STAAR Low-Grade Serous Ovarian Cancer Foundation, Not These Ovaries, and Verastem Oncology announced the launch of the LGSOC Resource Guide, a unique resource designed to support patients living with low-grade serous ovarian cancer (LGSOC), a rare and distinct form of ovarian cancer, along with their caregivers and advocates. Available at www.LGSOCAwarenessDay.org, the guide launches in conjunction with World Ovarian Cancer Day, a global effort to raise awareness...
-

Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib) for the Treatment of Active Psoriatic Arthritis in Adults

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib) for the Treatment of Active Psoriatic Arthritis in Adults...
-

ラピッド・メディカル™のTIGERTRIEVER™ 13、DISTALS試験で有望な90日転帰を示し、安全性・有効性に関する主要所見をさらに裏付け

オランダ、マーストリヒト＆イスラエル、ヨクネアム--(BUSINESS WIRE)--（ビジネスワイヤ） -- 先進的な脳卒中治療デバイスの主導的開発企業であるラピッド・メディカル™は本日、オランダ・マーストリヒトで開催された第 11回 欧州脳卒中学会（ESOC）において発表されたDISTALS無作為化臨床試験の完全結果を公表しました。同結果は、TIGERTRIEVER™ 13が末梢・中型血管閉塞（DMVO）脳卒中患者において脳への血流を安全に回復し、臨床転帰の改善につながる可能性があることを示しています。これらの所見は、内科的管理単独と比較して血流回復率が3倍に向上したことを示す先行結果をさらに裏付けるものであり（p<0.0001）、治療群では重篤な脳出血の発生は認められませんでした。 「今回の結果は、血流を安全に回復できることを示すとともに、適切な患者さんにとって臨床的に意義のある違いをもたらし得ることを示唆しています」と、UCLA所属でDISTALS試験の治験責任医師であるジェフリー・L・セーバー医師は述べています。同氏は続けて「重要なのは、デバイスと試験のいずれもが、末...
-

TIGERTRIEVER™ 13 de Rapid Medical™ démontre des résultats prometteurs à 90 jours dans l’essai DISTALS, renforçant ainsi les conclusions essentielles en matière d'innocuité et d’efficacité

MAASTRICHT, Pays-Bas et YOQNEAM, Israël--(BUSINESS WIRE)--Rapid Medical™, l'un des principaux développeurs de dispositifs avancés de traitement des AVC, annonce aujourd'hui les résultats complets de l'essai clinique randomisé DISTALS, présentés à la 11e conférence de l'organisation européenne des accidents vasculaires cérébraux (ESOC) à Maastricht, aux Pays-Bas, qui montrent que le TIGERTRIEVER™ 13 peut restaurer en toute sécurité le flux sanguin vers le cerveau et améliorer les résultats clini...
-

Der TIGERTRIEVER™ 13 von Rapid Medical™ zeigt vielversprechende 90-Tage-Ergebnisse in der DISTALS-Studie und untermauert damit die entscheidenden Erkenntnisse zu Sicherheit und Wirksamkeit

MAASTRICHT, Niederlande & YOKNEAM, Israel--(BUSINESS WIRE)--Rapid Medical™, ein führender Entwickler fortschrittlicher Geräte zur Schlaganfallbehandlung, gab heute die vollständigen Ergebnisse der randomisierten klinischen DISTALS-Studie bekannt, die auf der 11. Konferenz der European Stroke Organisation (ESOC) in Maastricht, Niederlande, vorgestellt wurden. Diese zeigen, dass TIGERTRIEVER™ 13 den Blutfluss zum Gehirn sicher wiederherstellen und die klinischen Ergebnisse bei Patienten mit einem...
-

Riassunto: TIGERTRIEVER™ 13 di Rapid Medical™ dimostra risultati promettenti a 90 giorni nello studio clinico DISTALS, confermando i risultati fondamentali in materia di sicurezza ed efficacia

MAASTRICHT, Paesi Bassi e YOKNEAM, Israele--(BUSINESS WIRE)--Rapid Medical™, sviluppatore leader di dipositivi avanzati per il trattamento degli ictus, ha annunciato oggi i risultati completi dello studio clinico randomizzato DISTALS, presentato in occasione dell'11ª European Stroke Organisation Conference (ESOC) a Maastricht, Paesi Bassi, che dimostrano come TIGERTRIEVER™ 13 è in grado di ripristinare in modo sicuro il flusso sanguigano e potrebbe migliorare i risultati clinici in pazienti col...
-

Samenvatting: TIGERTRIEVER™ 13 van Rapid Medical™ bewijst veelbelovende resultaten op 90 dagen in een DISTALS-studie die cruciale bevindingen inzake veiligheid en doeltreffendheid bevestigen

MAASTRICHT, Nederland & YOKNEAM, Israël--(BUSINESS WIRE)--Rapid Medical™, een toonaangevende ontwikkelaar van geavanceerde hulpmiddelen ter behandeling van infarcten, kondigde vandaag de volledige resultaten aan van de DISTALS gerandomiseerde klinische studie, voorgesteld tijdens de 11e ESOC (European Stroke Organisation Conference) in Maastricht, Nederland. Deze resultaten tonen aan dat TIGERTRIEVER™ 13 de bloedstroom naar de hersenen op veilige wijze kan herstellen en de klinische resultaten...